**Table 1: Study participant characteristics (n = 9,555), by vaccination status. P-values represent differences by vaccination status using Pearson’s chi-squared test**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Characteristic | Unvaccinated | Vaccinated | Overall | p-value |
| n | 2,154 | 7,401 | 9,555 |  |
| Age group (years) |  |  |  | < 0.001 |
| 18-24 | 423 (19.6) | 745 (10.1) | 1,168 (12.2) |  |
| 25-29 | 724 (33.6) | 2,571 (34.7) | 3,295 (34.5) |  |
| 30-34 | 611 (28.4) | 2,609 (35.3) | 3,220 (33.7) |  |
| 35-39 | 296 (13.7) | 1,109 (15.0) | 1,405 (14.7) |  |
| 40-44 | 100 (4.6) | 367 (5.0) | 467 (4.9) |  |
| BMI Category |  |  |  | 0.004 |
| Underweight | 52 (2.4) | 196 (2.7) | 248 (2.6) |  |
| Normal weight | 951 (44.2) | 3,468 (46.9) | 4,419 (46.3) |  |
| Overweight | 277 (12.9) | 993 (13.4) | 1,270 (13.3) |  |
| Obese | 123 (5.7) | 486 (6.6) | 609 (6.4) |  |
| No data | 751 (34.9) | 2,258 (30.5) | 3,009 (31.5) |  |
| Race and ethnicity |  |  |  | < 0.001 |
| Asian | 7 (0.3) | 73 (1.0) | 80 (0.8) |  |
| Black | 46 (2.1) | 54 (0.7) | 100 (1.1) |  |
| Hispanic | 47 (2.2) | 145 (2.0) | 192 (2.0) |  |
| Middle Eastern or North African | 7 (0.3) | 19 (0.3) | 26 (0.3) |  |
| Native Hawaiian or Pacific Islander | 3 (0.1) | 15 (0.2) | 18 (0.2) |  |
| Non-Hispanic white | 829 (38.5) | 2,926 (39.5) | 3,755 (39.3) |  |
| No data | 1,215 (56.4) | 4,169 (56.3) | 5,384 (56.4) |  |
| Parity |  |  |  | < 0.001 |
| Nulliparous | 1,513 (70.2) | 5,882 (79.5) | 7,395 (77.4) |  |
| Parous | 332 (15.4) | 824 (11.1) | 1,156 (12.1) |  |
| No data | 309 (14.4) | 695 (9.4) | 1,004 (10.5) |  |
| Education |  |  |  | < 0.001 |
| Less than college degree | 548 (25.4) | 1,093 (14.8) | 1,641 (17.2) |  |
| Completed college degree | 1,190 (55.3) | 5,284 (71.4) | 6,474 (67.8) |  |
| No data | 416 (19.3) | 1,024 (13.8) | 1,440 (15.1) |  |
| Relationship Status |  |  |  | < 0.001 |
| Not in steady relationship | 313 (14.5) | 962 (13.0) | 1,275 (13.3) |  |
| In steady relationship | 1,423 (66.1) | 5,236 (70.8) | 6,659 (69.7) |  |
| No data | 418 (19.4) | 1,203 (16.3) | 1,621 (17.0) |  |
| Geographic Region |  |  |  | < 0.001 |
| United Kingdom | 521 (24.2) | 2,574 (34.8) | 3,095 (32.4) |  |
| Europe | 519 (24.1) | 2,466 (33.3) | 2,985 (31.2) |  |
| United States and Canada | 931 (43.2) | 1,941 (26.2) | 2,872 (30.1) |  |
| Australia and New Zealand | 152 (7.1) | 222 (3.0) | 374 (3.9) |  |
| Other | 31 (1.4) | 198 (2.7) | 229 (2.4) |  |
| Vaccine type |  |  |  | N/Aa |
| Pfizer | 0 (0) | 4,938 (66.7) | 4,938 (51.7) |  |
| Moderna | 0 (0) | 1,322 (17.9) | 1,322 (13.8) |  |
| Johnson & Johnson | 0 (0) | 151 (2.0) | 151 (1.6) |  |
| Astrazeneca/adenovirus vector | 0 (0) | 650 (8.8) | 650 (6.8) |  |
| Whole/inactivated virus | 0 (0) | 44 (0.6) | 44 (0.5) |  |
| Unspecifiedb | 0 (0) | 296 (4.0) | 296 (3.1) |  |
| Unvaccinated | 2,154 (100) | 0 (0) | 2,154 (22.5) |  |

a No statistical test performed.

b Unspecified group contains one individual who received the protein subunit-based Novavax vaccine.